NEW YORK, Oct. 6, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL), a pharmaceutical development organization, today announced that it has appointed Bruce Murdoch as Head of its Anti-Infective division.
Bruce Murdoch has over 30 years experience within the pharmaceutical sector, and has held numerous senior positions. Bruce formerly held senior positions with Schering Plough, Pharmacia, Astra AB (now Astra Zeneca) and Rhone Poulenc.
Bruce's remit with Bioaccelerate is to further develop its Anti-Infective division and to manage the existing projects within it. This will involve arranging partnerships with various academia, research facilities and pharmaceutical companies, as well as overseeing the development of existing projects with the Anti-Infective pipeline.
Bruce Murdoch commented, " I am pleased to be appointed as Head of Anti-Infectives at Bioaccelerate. I am looking forward to the challenge of building and developing the Anti-infectives division and assisting in the development of Bioaccelerate to achieve its goals."
About Bioaccelerate
Bioaccelerate Holdings Inc. ("Bioaccelerate") is a company that acquires and develops pharmaceutical compounds which its management believes have potential for substantial medical and commercial value. Bioaccelerate currently has majority equity interests in 10 biotech companies, two of which are public. Bioaccelerate also holds minority equity interests in three Biotech companies, two of which are public. The companies which Bioaccelerate currently has equity interests in focus on five vertical therapeutic areas: cancer, cardiovascular, lifestyle, central nervous system and anti-infectives. Bioaccelerate's strategy utilizes a development network to accelerate the development of multiple early-stage compounds to Phase II/III clinical development. Management believes this creates a lower-risk business model as Bioaccelerate's network enables a timely and cost-effective passage from the discovery process up to Phase II/III where substantial incremental value can be created. For more information on the company please see the company's website at www.bioaccelerate.com
This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein.